Thomsen J J, Rentsch R L, Robach P, Calbet J A L, Boushel R, Rasmussen P, Juel C, Lundby C
Copenhagen Muscle Research Centre, Rigshospitalet, section 7652, 2100, Copenhagen Ø, Denmark.
Eur J Appl Physiol. 2007 Nov;101(4):481-6. doi: 10.1007/s00421-007-0522-8. Epub 2007 Aug 1.
The effects of recombinant human erythropoietin (rHuEpo) treatment on aerobic power (VO2max) are well documented, but little is known about the effects of rHuEpo on submaximal exercise performance. The present study investigated the effect on performance (ergometer cycling, 20-30 min at 80% of maximal attainable workload), and for this purpose eight subjects received either 5,000 IU rHuEpo or placebo every second day for 14 days, and subsequently a single dose of 5,000 IU/placebo weekly/10 weeks. Exercise performance was evaluated before treatment and after 4 and 11 weeks of treatment. With rHuEpo treatment VO2max increased (P<0.05) by 12.6 and 11.6% in week 4 and 11, respectively, and time-to-exhaustion (80% VO2max) was increased by 54.0 and 54.3% (P<0.05) after 4 and 11 weeks of treatment, respectively. However, when normalizing the workload to the same relative intensity (only done at time point week 11), TTE was decreased by 26.8% as compared to pre rHuEpo administration. In conclusion, in healthy non-athlete subjects rHuEpo administration prolongs submaximal exercise performance by about 54% independently of the approximately 12% increase in VO2max.
重组人促红细胞生成素（rHuEpo）治疗对有氧能力（最大摄氧量，VO2max）的影响已有充分记录，但rHuEpo对次最大运动表现的影响却知之甚少。本研究调查了其对运动表现的影响（测力计骑行，以最大可达到工作量的80%进行20 - 30分钟），为此，8名受试者每隔一天接受5000国际单位的rHuEpo或安慰剂，共14天，随后每周/10周接受单剂量5000国际单位/安慰剂。在治疗前以及治疗4周和11周后评估运动表现。使用rHuEpo治疗时，第4周和第11周的VO2max分别增加了12.6%和11.6%（P<0.05），治疗4周和11周后，力竭时间（80%VO2max）分别增加了54.0%和54.3%（P<0.05）。然而，当将工作量标准化为相同的相对强度时（仅在第11周时间点进行），与rHuEpo给药前相比，力竭时间减少了26.8%。总之，在健康的非运动员受试者中，给予rHuEpo可使次最大运动表现延长约54%，且与VO2max约12%的增加无关。
